<unk>  is used to treat dyspareunia. In the US it is indicated for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy (VVA), due to menopause. In the EU it is indicated for the treatment of moderate to severe symptomatic VVA in post-menopausal women who are not candidates for local vaginal oestrogen therapy. It is available as a 60 mg tablet that is taken by mouth once a day. The fact that<unk>  can be taken orally is advertised as an advantage over other products that are topically applied in the vaginal canal.<unk>  has not demonstrated any effects on libido, arousal, duration of intercourse or quality of orgasm in controlled clinical trials.
Ospemifene
Veristrat
Sesquimustard
Acolbifene
Toremifene
Tiotixene
Patiromer
Mitapivat